Akeso Biopharma

About:

Akeso Biopharma is a biopharmaceutical company committed to the discovery, development, and commercialization of therapies.

Website: http://www.akesobio.com

Top Investors: OrbiMed, Shenzhen Capital Group, Ally Bridge Group, Qianhai Fund of Funds, Loyal Valley Capital

Description:

The company has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line. The scale of the company's platform, hardware and software facilities, the number of new drug product lines, R & D team in the country are the same industry-leading level. Kang Fang biological has been with the international and domestic listed pharmaceutical companies to establish a cooperative relationship, the joint development of innovative antibodies to new drugs, is a strategic cooperation in the form of development of new drugs in the forerunner.

Total Funding Amount:

$470M

Estimated Revenue Range:

$1B to $10B

Headquarters Location:

Zhongshan, Anhui, China

Founded Date:

2012-01-01

Contact Email:

bd(AT)akesobio.com

Founders:

Li Baiyong, Wang Zhongmin, Xia Yu

Number of Employees:

501-1000

Last Funding Date:

2024-10-13

IPO Status:

Public

© 2025 bioDAO.ai